Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
FDA approvals in 2025: What changed and why it matters for ophthalmologists | Ophthalmology Times
Editor’s Note: This content was generated with the assistance of AI. From first-in-class pharmacologic therapies to next-generation retinal durability strategies and less invasive surgical platforms, 2025 emerged as a pivotal year for the ophthalmic pipeline. Over the past 12 months,…
PRIMAvera study: Central vision improvement with subretinal implant | Ophthalmology Times
The implant is shown placed subretinally in an eye with geographic atrophy due to age-related macular degeneration. (Image courtesy of Frank G. Holz, MD, FEBO, FARVO) (PRIMA) system implant restored central vision and led to a significant improvement in visual…
Refractory dry eye care: How systemic conditions change the game | Ophthalmology Times
Sezen Karakus, MD, discusses strategies for managing refractory dry eye in patients with systemic conditions, highlighting diagnosis, systemic coordination, and emerging treatment options. (Image credit: AdobeStock/Антон Сальников) Refractory dry eye in patients with systemic comorbidities can be challenging to manage…
The year in optometry: 10 stories that defined eye care in 2025 | Ophthalmology Times
(Image Credit: AdobeStock) The past year marked a pivotal period for optometry, with 2025 delivering meaningful clinical, regulatory, and legislative developments that reshaped eyecare practice. Innovation remained front and center as the US FDA authorized Essilor’s Stellest lenses for myopia…
Molecular insights and clinical experience: Extending anti-VEGF durability | Ophthalmology Times
(Image Credit: AdobeStock) A recent Ophthalmology Times Case-Based Roundtable focused on extended anti-VEGF treatment durability. Peter K. Kaiser, MD, the Chaney Family Endowed Chair in Ophthalmology Research and professor of ophthalmology at the Cleveland Clinic Lerner College of Medicine in…
Adopting Emerging Therapies in Dry Eye Care | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
The Evolution of MacTel Management: Integrating Neuroprotective Therapies Into Clinical Practice | Ophthalmology Times
Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Dante Pieramici, MD, FASRS; Dean Eliott, MD; and Charles C. Wykoff, MD, PhD, FASRS; provide an overview of macular…
Customized Clarity: Navigating IOL Options for Optimal Patient Care | Ophthalmology Times
Thanks for your interest in this podcast. Please read this important program information before listening. Episode Description In this podcast, experts Tanner Ferguson, MD, and Taj Nasser, MD, FWCRS, discuss the management of astigmatism at the time of cataract surgery,…
Evaluating Retinal Drying, Durability and IOP Management with Second-Generation Anti-VEGF Therapies in Retinal Vascular Diseases | Ophthalmology Times
This segment examines real-world comparisons between faricimab and aflibercept 8 mg in terms of retinal drying, durability, and intraocular pressure (IOP) management. Clinicians note that both agents extend treatment intervals modestly—often by about one additional week compared with standard 2…
Loading Dose Adjustments and Treatment Switching Strategies in Retinal Vascular Diseases | Ophthalmology Times
This segment explores real-world approaches to loading dose protocols and dosing interval management when initiating or switching anti-VEGF therapies. The panel discusses how closely clinicians adhere to recommended loading regimens and the practical barriers to doing so, such as payer…